Scholarlink

<p>While transcatheter paravalvular leak (PVL) closure offers a viable alternative to reoperation in high-risk patients, data from Japan remain limited. To address this, we retrospectively analyzed 28 consecutive patients who underwent percutaneous PVL closure at a single center in Japan between 2014 and 2022 (mitral, <i>n</i> = 23, aortic, <i>n</i> = 5; median follow-up, 2.0 years). We herein discuss real-time transesophageal echocardiography (TEE) with three-dimensional imaging, guided defect characterization, device sizing, and intra-procedural assessment. The study’s primary clinical endpoint was all-cause mortality, and its primary procedural endpoint was technical success, defined as a residual PVL &lt; moderate on intra-procedural TEE in the absence of emergency surgery or death. The secondary clinical endpoint was a composite of all-cause death, heart failure hospitalization, or reintervention. Technical success was achieved in 71% of patients. Device strategies evolved over time: in earlier cases, the Amplatzer Vascular Plug II (AVP II) and Amplatzer Duct Occluder II (ADO II) were used off-label, whereas later on, dedicated rectangular PVL devices (PLDs) became the preferred choice, typically requiring fewer devices per case. Hemolysis indices (e.g., lactate dehydrogenase and total bilirubin) improved following successful PVL reduction, and patients with a residual PVL &lt; moderate demonstrated superior clinical outcomes at follow-up. To facilitate benchmarking in elderly and renally impaired populations, we collected practical procedural metrics (procedure duration, contrast volume, and radiation exposure). This single-center experience demonstrates that transcatheter PVL closure is both feasible and effective in Japanese practice, while highlighting the importance of device selection and standardized intra-procedural TEE endpoints for procedural success.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Percutaneous paravalvular leak closure: clinical outcomes and practical insights from a single-center experience in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • Go Hashimoto,
  • Kenji Makino,
  • Atsuhiro Saito,
  • Shiho Ide,
  • Sari Waga,
  • Hiromasa Hayama,
  • Norihiro Kogame,
  • Yoshiyuki Yazaki,
  • Hiroki Niikura,
  • Hidehiko Hara

摘要

While transcatheter paravalvular leak (PVL) closure offers a viable alternative to reoperation in high-risk patients, data from Japan remain limited. To address this, we retrospectively analyzed 28 consecutive patients who underwent percutaneous PVL closure at a single center in Japan between 2014 and 2022 (mitral, n = 23, aortic, n = 5; median follow-up, 2.0 years). We herein discuss real-time transesophageal echocardiography (TEE) with three-dimensional imaging, guided defect characterization, device sizing, and intra-procedural assessment. The study’s primary clinical endpoint was all-cause mortality, and its primary procedural endpoint was technical success, defined as a residual PVL < moderate on intra-procedural TEE in the absence of emergency surgery or death. The secondary clinical endpoint was a composite of all-cause death, heart failure hospitalization, or reintervention. Technical success was achieved in 71% of patients. Device strategies evolved over time: in earlier cases, the Amplatzer Vascular Plug II (AVP II) and Amplatzer Duct Occluder II (ADO II) were used off-label, whereas later on, dedicated rectangular PVL devices (PLDs) became the preferred choice, typically requiring fewer devices per case. Hemolysis indices (e.g., lactate dehydrogenase and total bilirubin) improved following successful PVL reduction, and patients with a residual PVL < moderate demonstrated superior clinical outcomes at follow-up. To facilitate benchmarking in elderly and renally impaired populations, we collected practical procedural metrics (procedure duration, contrast volume, and radiation exposure). This single-center experience demonstrates that transcatheter PVL closure is both feasible and effective in Japanese practice, while highlighting the importance of device selection and standardized intra-procedural TEE endpoints for procedural success.